Perrigo Company (NYSE: PRGO; TASE) today announced that it has launched, through a distribution and supply agreement, methazolamide tablets, the generic equivalent to Neptazane™ tablets. This product is a component of the contingent rights Perrigo received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals, LLC and its affiliates in June of last year.
Methazolamide tablets are indicated for the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery. Estimated annual sales are approximately $12 million.
Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This launch reflects our continuing investment in new products, is a great addition to the portfolio of ophthalmic products Perrigo is marketing today and is just another example of our commitment to driving additional value for our shareholders."
Does your ADHD medication increase your risk of glaucoma?